Thus, in NSCLC patients (n = 21) treated with various aPD-1/aPD-L1 monotherapies, those with a greater increase in peripheral blood CD103+CD39+CD8+ T cell levels post-treatment also exhibited longer PFS [87]. This evidence concerns the gene CD8A and non-small cell lung carcinoma.